Roche Palo Alto LLC

Hoffmann-La Roche Inc.

F. Hoffmann-La Roche Ag

Joan Heather Hogg

David Michael Goldstein

James Patrick Dunn

Leyi Gong

Xiaochun Han

Yan Lou

Stacy W Remiszewski

Todd Richard Elworthy

Weiya Yun

Wylie Solang Palmer

Tania M Silva

Teresa Alejandra Trejo-Martin

Deborah Carol Reuter

Parcharee Tivitmahaisoon

Zachary Kevin Sweeney

Eric Brian Sjogren

Frederick Arthur Brookfield

Michael Patrick Dillon

Bernd Buettelmann

Mark Smith

Counde O'Yang

Achyutharao Sidduri

Steven Gregory Mischke

Dimitrios Stefanidis

Alam Jahangir

Robert Francis Kester

Kang Le

Humberto Bartolome Arzeno

Christophe Michoud

Shao-Yong Wu

Pravin Iyer

Steven Swallow

Taraneh Mirzadegan

Joshua Kennedy-Smith

Kristen Lynn McCaleb

Lubica Raptova

Jaehyeon Park

Yun-chou Tan

Geneviève N Boice

Jeffrey Wu

Sarah C Abbot

Florence Eustache

Weiling Liang

Tania Silva

Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein R, R, R, m, n and q are described in this application, and methods of using said compounds in the treatment of cancer. 

Azaheterocycles as BIR2 and/or BIR3 inhibitors

Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein W, Y, Z, R, R, Rand Rare as described in this application, and methods of using said compounds in the treatment of cancer. 

Indolines

Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein W, Y, Z, R, R, Rand Rare as described in this application, and methods of using the compounds in the treatment of cancer. 

Azaindolines

Disclosed are compounds of Formula (I), or pharmaceutically acceptable salts thereof, wherein W, Y, Z, R, R, Rand Rare as described in this application, and methods of using the compounds in the treatment of cancer. 

Compounds of formula I modulate JNK: wherein the variables are as defined herein.

JNK modulators

This application discloses novel pyrimidinyl pyridone derivatives according to formula I, wherein A, R, R, R, and m are defined as described herein, which inhibit JNK. The compounds disclosed herein are useful to modulate the activity of JNK and treat diseases associated with excessive JNK activity. The compounds are useful to treat autoimmune, inflammatory, metabolic, and neurological diseases as well as cancer. Also disclosed are compositions comprising the compound of formula I and methods of treatment comprising administering a therapeutically effective amount of the compound of formula I to a subject in need thereof.

Pyrimidinyl pyridone inhibitors of kinases

The invention relates to prodrugs of JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses prodrugs of JNK inhibitors, as described below in formula I: wherein m, n, p, q, Q, r, R, R, R, X, X, X, X, X, X, Y, Y, Zand Zare as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making said compounds, and corresponding compositions, disclosed herein.

Inhibitors of JNK

Compounds of formula I are effective modulators of JNK: wherein

Dihydroquinone and dihydronaphthridine inhibitors of JNK

Compounds of formula I, wherein R, R, R, X and Ar, are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions containing compounds of formula I useful for the prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. 

Non-nucleoside reverse transcriptase inhibitors

The present invention relates to a compounds according to formula I, methods for treating diseases mediated by human immunodeficieny virus by administration of a compound according to formula I and pharmaceutical compositions for treating diseases mediated by human immunodeficieny virus containing a compound according to formula I where R, R, R, R, R, R, Rand Rare as defined herein 

This invention relates to novel pyrazole derivatives of formula I wherein R1 to R4 are as defined in the summary and pharmaceutically acceptable salts and solvates thereof, methods to inhibit or modulate Human Immunodeficiency Virus (HIV) reverse transcriptase with compounds of formula I and pharmaceutical compositions containing of formula I admixed with at least one solvent, carrier or excipient. The compounds are useful for treating disorders in which HIV and genetically related viruses are implicated 

Nonnucleoside reverse transcriptase inhibitors

Growing community of inventors

Sunnyvale, CA, United States of America

Joan Heather Hogg